Jae-Won Hyun1, Yeseul Kim2, Gayoung Kim2, Su-Hyun Kim1, Ho Jin Kim3. 1. Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. 2. Division of Clinical Research, Research Institute and Hospital of National Cancer Center, Goyang, Korea. 3. Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea; Division of Clinical Research, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
Abstract
OBJECTIVES: Serum neurofilament light chain (sNfL) has been proposed a potential biomarker in multiple sclerosis (MS) based on mainly cross-sectional observations in Western population. To clarify clinical implication of sNfL, we longitudinally analysed sNfL levels at multiple time points in Korean MS patients undergoing alemtuzumab therapy. METHODS: Between 2016 and 2018, 144 sera from 17 MS patients treated with alemtuzumab at National Cancer Centre and 35 sera from 35 age- and gender-matched healthy controls (HCs) were collected for a longitudinal study with a mean 21-month follow-up. The sera were measured for sNfL levels using single molecule array. Patients were classified into two groups: evidence of disease activity (EDA) or no evidence of disease activity (NEDA). RESULTS: During alemtuzumab therapy, sNfL levels in EDA patients were significantly higher than those in NEDA patients and HCs (p < 0.001). In longitudinal analysis, the sNfL levels were consistently low in NEDA patients, while it consistently increased in radiologically and/or clinically active status in EDA patients. All sNfL levels in radiologically and/or clinically active status samples were higher than those in inactive status samples. CONCLUSION: These results suggest that sNfL is a promising monitoring biomarker for personalized therapeutics in MS patients.
OBJECTIVES: Serum neurofilament light chain (sNfL) has been proposed a potential biomarker in multiple sclerosis (MS) based on mainly cross-sectional observations in Western population. To clarify clinical implication of sNfL, we longitudinally analysed sNfL levels at multiple time points in Korean MSpatients undergoing alemtuzumab therapy. METHODS: Between 2016 and 2018, 144 sera from 17 MSpatients treated with alemtuzumab at National Cancer Centre and 35 sera from 35 age- and gender-matched healthy controls (HCs) were collected for a longitudinal study with a mean 21-month follow-up. The sera were measured for sNfL levels using single molecule array. Patients were classified into two groups: evidence of disease activity (EDA) or no evidence of disease activity (NEDA). RESULTS: During alemtuzumab therapy, sNfL levels in EDA patients were significantly higher than those in NEDA patients and HCs (p < 0.001). In longitudinal analysis, the sNfL levels were consistently low in NEDA patients, while it consistently increased in radiologically and/or clinically active status in EDA patients. All sNfL levels in radiologically and/or clinically active status samples were higher than those in inactive status samples. CONCLUSION: These results suggest that sNfL is a promising monitoring biomarker for personalized therapeutics in MSpatients.
Authors: Sarah Harris; Giancarlo Comi; Bruce A C Cree; Douglas L Arnold; Lawrence Steinman; James K Sheffield; Harry Southworth; Ludwig Kappos; Jeffrey A Cohen Journal: Eur J Neurol Date: 2021-08-23 Impact factor: 6.288
Authors: Joke Temmerman; Floris Van Der Veken; Sebastiaan Engelborghs; Kaat Guldolf; Guy Nagels; Dirk Smeets; Gert-Jan Allemeersch; Lars Costers; Marie B D'hooghe; Anne-Marie Vanbinst; Jeroen Van Schependom; Maria Bjerke; Miguel D'haeseleer Journal: J Clin Med Date: 2022-01-20 Impact factor: 4.241
Authors: Sarah A Eisenstein; Raveena S Boodram; Courtney L Sutphen; Heather M Lugar; Brian A Gordon; Bess A Marshall; Fumihiko Urano; Anne M Fagan; Tamara Hershey Journal: Front Neurosci Date: 2022-04-12 Impact factor: 4.677
Authors: Agnieszka Kulczyńska-Przybik; Maciej Dulewicz; Julia Doroszkiewicz; Renata Borawska; Ala Litman-Zawadzka; Daria Arslan; Alina Kułakowska; Jan Kochanowicz; Barbara Mroczko Journal: J Clin Med Date: 2022-07-15 Impact factor: 4.964